Skip to content

Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.

Effectiveness of Cod-Derived Omega Oil Enriched With Free Fatty Acids Against the Common Cold and Other Respiratory Infections in Healthy Icelandic Adults During the Influenza Season

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07314593
Acronym
OmegaCold FFA
Enrollment
400
Registered
2026-01-02
Start date
2025-12-19
Completion date
2027-08-31
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Infections

Keywords

Free Fatty Acids, Common Cold, respiratory infections, Omega-3, Influenza, COVID-19

Brief summary

The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses. Omega Cold is purified fish oil with 2% added free fatty acids, making it similar in that respect to less-purified fish oils. Participants aged 18-80 in generally good health will be recruited through Matís' consumer mailing list and social media advertisements. A total of 400 participants are planned: 100 in the winter of 2025-2026 and 300 in the winter of 2026-2027. Participants will be randomly assigned to two equal groups. One group will take Omega Cold orally twice a day for four months, while the other receives a placebo (vegetable oil) taken in the same way. They will not be asked to change any other habits. All participants will report weekly on their health and any cold or flu symptoms during the time they take the oil, using short questionnaires. The study is scheduled to begin in December 2025, when the oil will be sent to participants.

Detailed description

The purpose of the Omega Cold fish oil study is to determine whether fish oil enriched with free fatty acids affects people's susceptibility to viral infections, such as colds, flu or COVID, and the illnesses caused by such infections. Free fatty acids are present in untreated fish oil. However, the fish oil most commonly on the market today has been purified of free fatty acids. Omega Cold fish oil is purified fish oil with added free fatty acids in 2% concentration. This study is the first step in investigating whether fish oil with free fatty acids affects how often people get sick from viral infections, and whether consuming the fish oil affects the progression of the illness. Participants in the study are recruited by sending an email to Matís' consumer list and through advertisements on social media. The conditions for participation are to be between the ages of 18-80 and in generally good health. The aim is for 400 people to participate in the study - 100 in the winter of 2025 - 2026 and 300 in the winter of 2026 - 2027. The participants will be divided into two equal groups. One group will receive Omega Cold fish oil to take twice a day for four months. The other group is a placebo group and will receive vegetable oil to take in the same way. Participants will not be asked to change anything else in their consumption or behavior. All participants will be asked to record information about their health with regard to cold and flu symptoms weekly during the time they take the oil using short questionnaires.

Interventions

DIETARY_SUPPLEMENTOmega-3 oil with 2% Free Fatty Acids

Omega-3 oil enriched with Free Fatty Acids (2%) for oral intake

DIETARY_SUPPLEMENTVegatable oil

Vegetable oil as placebo

Sponsors

Landspitali University Hospital
Lead SponsorOTHER
Matis ohf.
CollaboratorUNKNOWN
Lipid Pharmaceuticals ehf.
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* to be in general good health * 18 to 80 years of age * willing and able to take fish oil orally.

Exclusion criteria

* younger than 18 years * older than 80 years

Design outcomes

Primary

MeasureTime frameDescription
Respiratory infectionsFour monthsParticipants will complete a short weekly questionnaire reporting any respiratory infection symptoms they experienced in the past seven days. If symptoms are present, they will be asked to provide additional details, including the type of symptoms, their duration, and their severity rated on numerical scales from 1 to 7 with 1 being mild and 7 being severe.

Countries

Iceland

Contacts

CONTACTAðalheiður Ólafsdóttir, B.Sc
adalheiduro@matis.is8585010
PRINCIPAL_INVESTIGATORMagnús Gottfreðsson, MD, PhD

Landspitali, University of Iceland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026